Clinical Analysi On Efficacy And Safety Of Lobaplatin Plus Etoposide And Cisplatin Plus Etoposide For Extensive-disease Stage Small Cell Lung Cancer

Objective:To study on the lobaplatin combined etoposide (EL) and cisplatin combined etoposide(EP) in treatmenting extensive-disease stage small cell lung cancer (ED stageSCLC),observe the recent and forward curative effect and adverse reaction,analysisrelated factors of curative effect,to provide the basis for selecting chemotherapy of EDstage SCLC.Methods:1.Retrospective analysis of the First Affiliated Hospital of Dalian Medical Universityduring2008~2012ED stage SCLC59patients,EL group is23cases,EP group is36cases.Two sets of scheme are complementary with anti-nausea,protecting stomachtreatment,while EP regimen give hydration,diuretic treatment,21days for a cycle.2.Continuous each2cycle evaluate curative effect (RECIST1.1),evaluate adversereaction after completing a cycle chemotherapy (CTCAE4.0),follow-up of the time ofdisease progression and death time.3.All data were analyzed by SPSS17.0software.Apply chi-square test, Fisher’s exactprobability method and Wilcoxon test, analysis of RR, DCR, curative effect between thetwo groups of related factors, survival rate, adverse reaction.Kaplan Meier-methodanalysis of PFS, OS,between the two groups use log-rank test.Results:1.First line treated patients:1.1Objective effective RR for EL group is55.6%,EP group is37.0%,DCR for EL groupis66.7%, EP group is59.3%,there was no statistically significant difference(P>0.05).1.2Two group of objective and efficient RR,there was no significant correlationbetween DCR and gender,age,smoking index,the transfer part,KPS score(P>0.05).1.3EL group of1year survival rate is55.6%,EP44.4%,2year survival rate EL group is 11.1%,EP group is14.8%,there was no statistically significant difference(P>0.05).1.4Median PFS is EL group10.3months, EP7.1months and the median OS for ELgroup13.87months,EP12.17months,there was no statistically significantdifference(P>0.05).2. The retreatment patients:2.1Objective effective RR for EL group is42.9%,EP group is33.3%,DCR for EL groupis64.3%,EP group is66.7%,there was no statistically significant difference(P>0.05).2.2Two group of objective and efficient RR,disease control rates DCR withgender,age,smoking index,the transfer part,KPS score had no significantcorrelation(P>0.05).2.3EL group of1year survival rate is57.1%, EP group is55.6%,2year survival rate ELgroup is21.4%,the EP group is11.1%,there was no statistically significantdifference(P>0.05).2.4Median PFS was EL group9.67months,EP7.33months,comparing the twogroups,there was statistically significant difference(P<0.05),the median OS for ELgroup15.33months,EP group18.33months,there was no statistically significantdifference(P>0.05).3. Adverse effect:3.1Main adverse effect of two groups of patients was marrow inhibition andgastrointestinal reaction.3.2Incidence of Leukocytopenia EL group is69.6%,the EP group is91.7%,incidence ofplatelets decrease EL group is43.5%,the EP group is19.4%,incidence of gastrointestinalreaction EL group is13.0%,the EP group is58.3%,there was statistically significantdifference in two groups(P<0.05).3.3Further classification comparison,the incidence of leukocytopenia,gastrointestinalreaction in3~4grade was statistically significant(P<0.05),the incidence of EP groupwas higher than EL group;EL group was higher than EP incidence ofplatelets,classification comparison there was no statistically significantdifference(P>0.05).4. EL regimen for asymptomatic brain metastases in1case,the completion of six cyclesof chemotherapy,imaging of brain metastases disappear,curative effect evaluation ofPR,display effect. Conclusion:The fist line treatment of patients with EL regimen comparing with EP in recent andforward curative effect are similar.The retreatment EL regimen progression-free surialin patients with PFS solutions better than EP,two groups in the near future curativeeffect, overall survival are similar.EL regimen in platelet decrease is increasing thanEP,leukopenia,gastrointestinal tract reaction,especially3~4level significantly lowerthan EP group.EL group show efficacy for the treatment of asymptomatic brainmetastases of SCLC.